期刊文献+
共找到672篇文章
< 1 2 34 >
每页显示 20 50 100
Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3β/β-catenin in urinary bladder cancer patients 预览
1
作者 Niharika Maurya Rinni Singh +4 位作者 Apul Goel Atin Singhai Uday Pratap Singh Vinita Agrawal Minal Garg 《世界临床肿瘤学杂志(英文版)》 2019年第4期166-182,共17页
BACKGROUND Aberrant activation of phosphorylated form of glycogen synthase kinase-3β[pS9GSK-3β(Serine 9 phosphorylation)] is known to trigger Wnt/β-catenin signal cascade but its clinicohistopathological implicatio... BACKGROUND Aberrant activation of phosphorylated form of glycogen synthase kinase-3β[pS9GSK-3β(Serine 9 phosphorylation)] is known to trigger Wnt/β-catenin signal cascade but its clinicohistopathological implications in bladder carcinogenesis remain unknown. AIM To investigate the diagnostic and prognostic relevance of expressions of pS9GSK- 3β,β-catenin and its target genes in the pathobiology of bladder cancer. METHODS Bladder tumor tissues from ninety patients were analyzed for quantitative expression and cellular localization of pS9GSK-3β by immunohistochemical (IHC) staining. Real time-quantitative polymerase chain reaction and IHC were done to check the expression of β-catenin, Cyclin D1, Snail and Slug at transcriptome and protein level respectively. Clinicohistopathological variables were obtained from histology reports, follow up and OPD visits of patients. Expressions of the markers were statistically correlated with these variables to determine their significance in clinical setting. Results were analysed using SPSS 20.0 software.RESULTS Aberrant (low or no membranous/high nuclear/high cytoplasmic) expression of pS9GSK-3β was noted in 51% patients and found to be significantly associated with tumor stage and tumor grade (P = 0.01 and 0.04;Mann Whitney U test). Thirty one percent tumors exhibited aberrant co-expression of pS9GSK-3β and β–catenin proteins and showed strong statistical association with tumor stage, tumor type, smoking/tobacco chewing status (P = 0.01, 0.02 and 0.04, Mann- Whitney U test) and shorter overall survival probabilities of patients (P = 0.02;Kaplan Meier test). Nuclear immunostaining of Cyclin D1 in tumors with altered pS9GSK-3β/β–catenin showed relevance with tumor stage, grade and type. CONCLUSION β–catenin and pS9GSK-3β proteins are identified as markers of diagnostic/prognostic significance in disease pathogenesis. Observed histopathological association of Cyclin D1 identifies it as marker of potential relevance in tumors with altered pS9GSK-3β/β-cateni 展开更多
关键词 PATHOBIOLOGY Target GENES Tumor stage and grade Wnt/β–catenin signal CASCADE UROTHELIAL carcinoma of BLADDER
在线阅读 免费下载
The preoperative serum cystatin-C as an independent prognostic factor for survival in upper tract urothelial carcinoma
2
作者 Ping Tan Ming Shi +8 位作者 Jie Chen Hang Xu Nan Xie Huan Xu Yong Jiang Jian-Zhong Ai Liang-Ren Liu Lu Yang Qiang Wei 《亚洲男性学杂志:英文版》 SCIE CAS CSCD 2019年第2期163-169,共7页
Cystatin-C(Cys-C)has been reported as a valuable prognostic biomarker in various malignancies.However,its effect on upper tract urothelial carci noma(UTUC)patie nts has not bee n investigated before.Thus,to explore th... Cystatin-C(Cys-C)has been reported as a valuable prognostic biomarker in various malignancies.However,its effect on upper tract urothelial carci noma(UTUC)patie nts has not bee n investigated before.Thus,to explore the impact of Cys-C on survival outcomes in patients undergoing radical nephroureterectomy(RNU),a total of 538 patients with UTUC who underwent RNU between 2005 and 2014 in our center(West China Hospital,Chengdu,China)were included in this study.Kaplan-Meier method and Cox regressi on an a lyses were performed to assess the relationship betwee n Cys-C and survival outcomes using SPSS versi on 22.0.The cutoff value of Cys-C was set as 1.4 mg I1 using the receiver operating characteristic(ROC)curves and Youden index.The mean age of patients included was 66.1±11.1 years,and the media n follow-up durati on was 38(interquartile ran ge:19-56)mon ths.Overall,162(30.1%)patients had elevated Cys-C,and they were much older and had worse renal function than those with Cys-C<1.4 mg I^-1(both P<0.001).Meanwhile,Kaplan-Meier analysis revealed that the group with elevated Cys-C had worse cancer-specific survival(CSS,P=0.001),disease recurrence-free survival(RFS,P=0.003),and overall survival(OS,P<0.001).Multivariable Cox analysis suggested that the elevated Cys-C was identified as an independent prognostic predictor of CSS(hazard ratio[HR]:1.997,95%confidential interval[CI]:1.331-2.996),RFS(HR:1.429,95%CI:1.009-2.023),and OS(HR:1.989,95%CI:1.366-2.896).In conclusion,our result revealed that the elevated preoperative serum Cys-C was significantly associated with worse outcomes in UTUC patients undergoing RNU. 展开更多
关键词 CYSTATIN-C prognosis RADICAL NEPHROURETERECTOMY upper TRACT UROTHELIAL carcinoma
Chinese guidelines for diagnosis and treatment of urothelial carcinoma of bladder 2018 (English version) 预览
3
作者 National Health Commission of the People’s Republic of China 《中国癌症研究:英文版》 SCIE CAS CSCD 2019年第1期49-66,共18页
Contents1. Overview2. Risk factors for urothelial carcinoma of bladder3. Diagnosis of urothelial carcinoma of bladder3.1 Signs and symptoms of urothelial carcinoma of bladder3.1.1 Symptoms3.1.2 Signs3.2 Imaging examin... Contents1. Overview2. Risk factors for urothelial carcinoma of bladder3. Diagnosis of urothelial carcinoma of bladder3.1 Signs and symptoms of urothelial carcinoma of bladder3.1.1 Symptoms3.1.2 Signs3.2 Imaging examination3.2.1 Ultrasonography3.2.2 CT examination3.2.3 MRI examination3.2.4 IVU3.2.5 Chest plain X-ray film/CT plain scan3.2.6 Bone scintigraphy3.2.7 Positron emission tomography-CT (PET-CT). 展开更多
关键词 CHINESE GUIDELINES DIAGNOSIS UROTHELIAL
在线阅读 下载PDF
Bladder urothelial carcinoma extending to rectal mucosa and presenting with rectal bleeding 预览
4
作者 Andrew M Aneese Vinayata Manuballa +1 位作者 Mitual Amin Mitchell S Cappell 《世界胃肠内镜杂志:英文版(电子版)》 2017年第6期282-295,共14页
An 87-year-old-man with prostate-cancer-stage-T1cGleason-6 treated with radiotherapy in 1996, recurrent prostate cancer treated with leuprolide hormonal therapy in 2009, and bladder-urothelial-carcinoma in situ treate... An 87-year-old-man with prostate-cancer-stage-T1cGleason-6 treated with radiotherapy in 1996, recurrent prostate cancer treated with leuprolide hormonal therapy in 2009, and bladder-urothelial-carcinoma in situ treated with Bacillus-Calmette-Guerin and adriamycin in 2010, presented in 2015 with painless, bright red blood per rectum coating stools daily for 5 mo. Rectal examination revealed bright red blood per rectum; and a hard, fixed, 2.5 cm × 2.5 cm mass at the normal prostate location. The hemoglobin was 7.6 g/d L(iron saturation = 8.4%,indicating iron-deficiency-anemia). AbdominopelvicCT-angiography revealed focal wall thickening at the bladder neck; a mass containing an air cavity replacing the normal prostate; and adjacent rectal invasion. Colonoscopy demonstrated an ulcerated, oozing, multinodular, friable, 2.5 cm × 2.5 cm mass in anterior rectal wall, at the usual prostate location. Histologic and immunohistochemical analysis of colonoscopic biopsies of the mass revealed poorly-differentiatedcarcinoma of urothelial origin. At visceral angiography, the right-superior-rectal-artery was embolized to achieve hemostasis. The patient subsequently developed multiple new metastases and expired 13 mo postembolization. Comprehensive literature review revealed 16 previously reported cases of rectal involvement from bladder urothelial carcinoma, including 11 cases from direct extension and 5 cases from metastases. Patient age averaged 63.7 ± 9.6 years(all patients male). Rectal involvement was diagnosed on average 13.5 ± 11.8 mo after initial diagnosis of bladder urothelial carcinoma. Symptoms included constipation/gastrointestinal obstruction-6, weight loss-5, diarrhea-3, anorexia-3, pencil thin stools-3, tenesmus-2, anorectal pain-2, and other-5. Rectal examination in 9 patients revealed annular rectal constriction-6, and rectal mass-3. The current patient had the novel presentation of daily bright red blood per rectum coating the stools simulating hemorrhoidal bleeding; the novel mechanism of direct bladder u 展开更多
关键词 膀胱癌症 UROTHELIAL Uroepitheilal 过渡房间 直肠穿入 癌症传播了 降低胃肠的流血 COLONOSCOPY
在线阅读 免费下载
肾移植术后发生恶性肿瘤的临床分析 被引量:1
5
作者 曲星珂 徐涛 +4 位作者 马凯 张晓威 李晓丹 黄晓波 王晓峰 《中华泌尿外科杂志》 CSCD 北大核心 2017年第S1期45-48,共4页
目的 探讨肾移植术后发生恶性肿瘤的临床特点和诊治方法.方法 回顾性分析1991年5月至2016年10月我们收治的24例肾移植术后发生恶性肿瘤患者的临床资料.男14例,女10例.年龄42~61岁,平均54.5岁.22例移植前行血液透析,时程6~46个月,平均14.... 目的 探讨肾移植术后发生恶性肿瘤的临床特点和诊治方法.方法 回顾性分析1991年5月至2016年10月我们收治的24例肾移植术后发生恶性肿瘤患者的临床资料.男14例,女10例.年龄42~61岁,平均54.5岁.22例移植前行血液透析,时程6~46个月,平均14.6个月;2例行腹膜透析,时程15个月.19例为首次移植,5例为二次移植.本院肾移植术后发生肿瘤13例,发生率2.9%(13/445).24例中19例为尿路上皮癌,占79%(9例肾盂癌合并输尿管尿路上皮癌,8例原发输尿管尿路上皮癌,2例原发膀胱尿路上皮癌),另有移植肾和原肾的透明细胞癌各1例,甲状腺癌、结肠癌、淋巴瘤各1例.结果 除1例淋巴瘤患者行化疗外,其余23例均行肿瘤根治术.21例泌尿系肿瘤患者中,2例行开放性手术(1例行全泌尿系同期根治性切除术,1例移植肾肿瘤部分切除术),2例行膀胱癌经尿道电切术,17例行腹腔镜下肾盂癌、输尿管癌根治术.3例患者于1年内复发行二次手术、2例患者二次复发行第3次手术.随访18例至今术后生存情况良好;另有5例术后肿瘤复发,3年内死亡.结论 移植术后患者高发恶性肿瘤,与其免疫抑制治疗和肾移植术的影响密切相关.肾移植后发生的恶性肿瘤主要为泌尿系肿瘤.治疗关键在于早期发现、早期治疗. 展开更多
关键词 肾移植 尿路上皮
长非编码RNA UCA1在肿瘤中的研究进展
6
作者 严大理 曹海霞 冯继锋 《国际肿瘤学杂志》 CAS 2017年第2期108-111,共4页
长非编码RNA尿路上皮癌胚抗原1(UCAl)首先于膀胱癌组织中发现并命名,在多种肿瘤组织中如膀胱癌、卵巢癌、肺癌等明显高表达,表现为原癌基因的功能.UCA1可调节肿瘤细胞的增殖、凋亡、转移、侵袭等,在肿瘤的发生、发展中起重要作用,可... 长非编码RNA尿路上皮癌胚抗原1(UCAl)首先于膀胱癌组织中发现并命名,在多种肿瘤组织中如膀胱癌、卵巢癌、肺癌等明显高表达,表现为原癌基因的功能.UCA1可调节肿瘤细胞的增殖、凋亡、转移、侵袭等,在肿瘤的发生、发展中起重要作用,可作为肿瘤诊断、预后及药物敏感性预测的一种新的生物学标志物,并有望成为肿瘤治疗的新靶点. 展开更多
关键词 肿瘤 原癌基因 尿路上皮癌胚抗原1 UROTHELIAL carcinoma ASSOCIATED 1
Contemporary management of upper tract urothelial cell carcinoma 预览
7
作者 Kellen Choi Ryan McCafferty Samuel Deem 《世界临床泌尿杂志》 2017年第1期1-9,共9页
Upper tract urothelial cell carcinoma(UTUCC),formerly known as transitional cell carcinoma of the upper urinary tract,is a rare oncologic disease in Western countries.Thus its disease process and its management are no... Upper tract urothelial cell carcinoma(UTUCC),formerly known as transitional cell carcinoma of the upper urinary tract,is a rare oncologic disease in Western countries.Thus its disease process and its management are not as well defined as other urologic cancers.We are reviewing the current evidence based literature available to develop a plan for the treatment of UTUCC.A PubMed search was completed using the key words“upper tract urothelial cell carcinoma”,“epidemiology”,“risk factor”,“treatment”and“prognosis”.Six hundred fifty two articles were found.We narrowed our search to articles published between January 2004 and June 2016 for a more contemporary review of the topic.Four hundred seventy articles were then available for review.Further detailed search was performed for relevance on the topic and hundred one articles were selected for the review.Many risk factors have been found to be associated with the development of UTUCC,including tobacco use.Patients are often asymptomatic and may only present with microscopic or gross hematuria.Tumor grade and stage are pivotal in determining the treatment options for UTUCC.Advancements in endoscopic techniques have aided in the diagnosis,grading and treatment of this disease.Treatment options include topical therapy,with combinations of methotrexate,vinblastine,doxorubicin and cisplatin or gemcitibine or cisplatin,endoscopic resection,segmental ureterectomy and ureteral implantation,and nephroureterectomy,including bladder cuff.Treatment recommendations depend on tumor grade and stage,renal function,tumor location and the patient’s prognosis.There are currently no tissue or blood-based biomarkers available to accurately monitor the disease.Further studies of gene expression and biomarkers may hopefully improve the management of this disease.Although rare in many countries,UTUCC is becoming more prevalent due to exposure to carcinogenic herbal remedies and other identifiable risk factors.Numerous treatment modalities,both surgical and chemotherapeut 展开更多
关键词 UROTHELIAL cell carcinoma Diagnosis UPPER TRACT EPIDEMIOLOGY Risk factors Treatment PROGNOSIS
在线阅读 免费下载
Radical cystectomy and en-bloc resection of enterovesical fistula from bladder cancer 预览
8
作者 Zi Qin Ng Willy KW Low +2 位作者 Sathiyananthan Jr Pradeep Subramanian Joel Stein 《世界临床泌尿杂志》 2017年第1期30-33,共4页
Enterovesical fistulae secondary to benign or malignant bowel disease are not uncommonly reported in the literature.However,bladder malignancy as the primary pathology is exceedingly rare.We report a case of muscle in... Enterovesical fistulae secondary to benign or malignant bowel disease are not uncommonly reported in the literature.However,bladder malignancy as the primary pathology is exceedingly rare.We report a case of muscle invasive urothelial carcinoma of bladder with an enterovesical fistula to a loop of small bowel.The patient first presented with signs and symptoms of per rectal bleeding,haematuria,pneumaturia,faecaluria and rectal micturition.Her initial biochemistry test revealed significant metabolic acidosis with normal anion gap and hypokalemia.A computed tomography abdomen/pelvis with rectal contrast demonstrated an enterovesical fistula from the dome of bladder to a loop of small bowel.The patient underwent radical cystectomy with enbloc resection of a loop of involved ileum and sigmoid colon due to the intraoperative findings of the sigmoid colon adherent to the tumour.The published literature is reviewed,focusing on the incidence,diagnostic modality and treatment strategies available for this rare condition. 展开更多
关键词 BLADDER cancer Enterovesical FISTULA Enbloc RESECTION MALIGNANT FISTULA UROTHELIAL carcinoma
在线阅读 免费下载
UCA1在消化道肿瘤中的表达及作用机制
9
作者 赵义 燕善军 王启之 《国际肿瘤学杂志》 CAS 2017年第2期142-144,共3页
尿路上皮癌相关1基因(UCA1)是一种长非编码RNA,无编码蛋白质的功能.UCA1在多种肿瘤中呈高表达,在肿瘤的发生发展中发挥重要作用.研究表明UCA1在胃癌、结直肠癌和肝癌等消化道肿瘤中发挥致癌基因作用,参与调控细胞的增殖、转移和化疗... 尿路上皮癌相关1基因(UCA1)是一种长非编码RNA,无编码蛋白质的功能.UCA1在多种肿瘤中呈高表达,在肿瘤的发生发展中发挥重要作用.研究表明UCA1在胃癌、结直肠癌和肝癌等消化道肿瘤中发挥致癌基因作用,参与调控细胞的增殖、转移和化疗耐药性. 展开更多
关键词 消化道肿瘤 尿路上皮癌相关1 UROTHELIAL CARCINOMA ASSOCIATED 1
尿路上皮癌胚抗原1对口腔癌细胞侵袭迁移及增殖影响的实验研究 被引量:3
10
作者 杨勇涛 杨宏宇 +3 位作者 王宇帆 沈时岳 李明华 秦嘉若 《中华口腔医学杂志》 CAS CSCD 北大核心 2016年第1期36-41,共6页
目的 探讨长链非编码RNA尿路上皮癌胚抗原1(urothelial carcinoembryonic antigen 1,UCA1)对口腔癌细胞系SCC15和CAL27侵袭、迁移及增殖能力的影响.方法 瞬时转染UCA1-siRNA沉默SCC15和CAL27细胞中长链非编码RNA UCA1的表达,以阴性干... 目的 探讨长链非编码RNA尿路上皮癌胚抗原1(urothelial carcinoembryonic antigen 1,UCA1)对口腔癌细胞系SCC15和CAL27侵袭、迁移及增殖能力的影响.方法 瞬时转染UCA1-siRNA沉默SCC15和CAL27细胞中长链非编码RNA UCA1的表达,以阴性干扰RNA为对照组,在实验的5、24、48、72、96 h为观测点.利用实时荧光定量核酸扩增反应(quantitative real time,qRT)-PCR方法检测UCA1干扰效果;通过蛋白质印迹法检测SCC15和CAL27中UCA1实验组及对照组基质金属蛋白酶(matrix metalloproteinase 9,MMP-9)蛋白表达水平;通过划痕实验及Transwell实验检测其侵袭及迁移能力;通过CCK-8实验检测细胞增殖能力.结果 SCC15和CAL27细胞的UCA1有效沉默,SCC15和CAL27两株细胞系UCA1干扰效率分别为86.45%(P<0.001)和78.24% (P<0.001);沉默后细胞的迁移侵袭及增殖能力均减弱,CAL27对照组与实验组的迁移、侵袭穿膜细胞分别为(719.20±92.36)和(208.00±25.58)个(P=0.000 7);(363.40±45.96)和(164.80±24.68)个(P=0.005 2);SCC15对照组与实验组的迁移、侵袭穿膜细胞分别为(437.20±54.75)和(145.80±23.31)个(P=0.001 1)、(249.80±38.41)和(63.80±11.11)个(P=0.001 6);通过检测并计算出实验组相对于对照组各个时间点的相对增殖率,即实验组中24、48、72和96 h与对照组中同一时间点比较,SCC 15:R24 h=0.870、R48 h=0.863、R72h=0.643、R96h=0.732;CAL27:R24h=0.913、R48 h=0.829、R72 h=0.756、R96 h=0.705) (P<0.05);MMP-9蛋白表达量下降.结论 UCA1能通过调节MMP-9蛋白的表达增强其侵袭迁移能力,并能促进其增殖能力,从而在口腔癌侵袭进展中发挥作用. 展开更多
关键词 口腔鳞状细胞癌 口腔肿瘤 尿路上皮癌胚抗原1 UROTHELIAL carcinoembryonic ANTIGEN 1
Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract 预览
11
作者 Tsunenori Kondo Toshio Takagi Kazunari Tanabe 《世界临床肿瘤学杂志》 2015年第6期237-251,共15页
Lymphadenectomy for urothelial carcinoma of the upper urinary tract has attracted the attention of physicians.The mapping study of lymphatic spread has shown that a relatively wide area should comprise the regional no... Lymphadenectomy for urothelial carcinoma of the upper urinary tract has attracted the attention of physicians.The mapping study of lymphatic spread has shown that a relatively wide area should comprise the regional nodes for tumors of the right renal pelvis or the right upper two-thirds of the ureter.A prospective study showed that an anatomical templatebased lymphadenectomy significantly improved patient survival in tumors of the renal pelvis.This benefit was more evident for patients with pT2 stage tumors or higher.The risk of regional node recurrence is significant reduced by template-based lymphadenectomy,which is likely to be associated with improved patient survival.The removal of lymph node micrometastases is assumed to be the reason for therapeutic benefit following lymphadenectomy.The number of resected lymph nodes can be used to assess the quality of lymphadenectomy,but not to determine the extent of lymphadenectomy.The guidelines currently recommend lymphadenectomy for patients with muscle-invasive disease,even though the current recommendation grades are still low.The present limitation of lymphadenectomy is the lack of standardization of the extent of lymphadenectomy and the randomized trials.Further studies are warranted to collect the evidence to support lymphadenectomy. 展开更多
关键词 LYMPHADENECTOMY LYMPH node EXCISION UROTHELIAL carcinoma Treatment outcome THERAPEUTIC uses Diagnosis Guideline
在线阅读 免费下载
From the battlefield to the bladder:The development of thioTEPA 预览
12
作者 Sean M Gallagher Steven H Selman 《世界临床泌尿杂志》 2014年第3期195-200,共6页
Effective medications for the treatment of cancer were nonexistent in the early twentieth century.Ironically the widespread use of toxic chemical weapons,chlorine and sulfur mustard gas,during the“Great War”led to t... Effective medications for the treatment of cancer were nonexistent in the early twentieth century.Ironically the widespread use of toxic chemical weapons,chlorine and sulfur mustard gas,during the“Great War”led to the first successful chemotherapeutic treatment of cancer patients.Soon after the introduction of poisonous gas on the battlefield,reports of the resulting pancytopenia in exposed combatants appeared in the medical literature.The biologic effect of chemical weaponry on rapidly dividing cells eventually was recognized for its salutary potential in the treatment of cancer.Once this potential was appreciated,hundreds of similar compounds were synthesized and evaluated as chemotherapeutic agents.One such compound,thioTEPA,would eventually open the era of intravesical treatment of urothelial cancer. 展开更多
关键词 ThioTEPA BLADDER CANCER UROTHELIAL CANCER INTRAVESICAL chemotherapy Mustard gas MITOMYCIN C
在线阅读 免费下载
MiRNA in bladder carcinogenesis:A review 预览
13
作者 Nelson Dip Sabrina T Reis +8 位作者 Nayara I Viana Denis R Morais Caio M Moura Betina Katz Daniel K Abe Alexandre Iscaife Iran A Silva Miguel Srougi Kátia RM Leite 《世界临床泌尿杂志》 2014年第3期238-248,共11页
Bladder cancer(BC)is the second urological malignancy in incidence,currently being one of the most neoplasms studied with profile and biology poorly defined.In the world,BC is responsible by about 386000 new cases and... Bladder cancer(BC)is the second urological malignancy in incidence,currently being one of the most neoplasms studied with profile and biology poorly defined.In the world,BC is responsible by about 386000 new cases and 150000 deaths annually with considerable economic impact and high costs for health systems.After its discovery more than 20 years,micro RNAs(miRNAs)have been recognized as molecules that work specifically in post-transcriptional control in majority of eukaryote genomes.MiRNAs are a family of small noncoding RNAs of 19-25 nucleotides in length,expressed in a wide variety of organisms,comprising plants,worms and mammals,including humans.They have a fundamental role in physiological and pathological processes in organs and tissues in a context-dependent manner.This review brings new roles of protective and oncogenic miRNAs linked to carcinogenesis of urothelial carcinoma of the bladder,and associated with behavior of disease.Many studies have demonstrated promising roles of miRNAs working as diagnostic and prognostic biomarkers or involved in target therapies,consolidating miRNAs as crucial players in human cancer.This review allowed a reflection about the true functions of miRNAs in bladder carcinogenesis.Not only by their wide capacities of action,but also by abilities in define the cell date.The future of anti-tumor target therapies will be based not in one,but in groups of miRNAs working together in several steps of carcinogenic process,being able to identify the disease,predicting behavior and effectively treat bladder cancer. 展开更多
关键词 BLADDER cancer UROTHELIAL CARCINOMA MIRNA Biomarkers
在线阅读 免费下载
Pyonephrosis as a sign of sarcomatoid carcinoma of the renal pelvis 预览
14
作者 Sergio Fernández-Pello Victoria Venta +2 位作者 Iván González Rodrigo Gil Carmen Luz Menéndez 《世界临床病例杂志》 2014年第6期215-218,共4页
We report the case of an urgent nephrectomy because of a pyonephrosis and sepsis due to an unsuspected sarcomatoid transitional cell carcinoma,an infrequent subtype with a bad oncological prognosis.we present a 58-yea... We report the case of an urgent nephrectomy because of a pyonephrosis and sepsis due to an unsuspected sarcomatoid transitional cell carcinoma,an infrequent subtype with a bad oncological prognosis.we present a 58-year-old man assessed by internal medicine for a general syndrome and weakness many months previously.A pyonephrotic kidney was observed at abdominal computed tomography in the context of septic shock,without suspecting the underlying cause.The pathology report described a sarcomatoid transitional cell carcinoma.sarcomatoid transitional cell carcinoma is an invasive and infrequent subtype of urothelial tumors.The symptoms are often the same as other renal masses;however,in this case,sepsis and pyonephrosis were the rare initial symptoms. 展开更多
关键词 UROTHELIAL CARCINOMA RENAL PELVIS SARCOMATOID
在线阅读 免费下载
Potential of metastin and metastin receptor as biomarkers for urological cancers 预览
15
作者 Sunao Shoji Haruhiro Sato +6 位作者 Tetsuro Tomonaga Hakushi Kim Shuichi Soeda Mayura Nakano Toyoaki Uchida Toshiro Terachi Koichi Takeya 《世界临床泌尿杂志》 2013年第2期10-14,共5页
AIM:To investigate the current state of the research of metastin and metastin receptor in the urological cancer field.METHODS:For analyzing the value of metastin and metastin receptor as molecular biomarkers for the p... AIM:To investigate the current state of the research of metastin and metastin receptor in the urological cancer field.METHODS:For analyzing the value of metastin and metastin receptor as molecular biomarkers for the patients with urological cancer,MEDLINE database searches were performed using these terms:metastin,KISS1,kisspeptin,renal(cell)carcinoma(RCC),kidney cancer or urothelial cancer or bladder cancer or prostate cancer or testicular cancer(tumor).Since the articles were evaluated by the validity of the articles based on plausibility,credibility,and evidence levels,the articles were graded according to their level of evidence,using the grading system defined by the Oxford Centre for Evidence-based Medicine.RESULTS:A total of six clinical studies published by individual institutions between 2003 and 2013 were included in this review.The article numbers for each of the evidence levels 2a and 2b were three(50%)and three(50%),respectively.Immunohistochemistry and reverse transcriptase-polymerase chain reaction using tumor tissues were performed to analyze in five articles(83%)and in one article(17%).The value of metastin and/or metastin receptor as molecular biomarkers in clear cell RCC,upper tract urothelial carcinoma,and bladder cancer was evaluated by multivariate analysis.Low expression of metastin receptor in clear cell RCC and low expression of metastin in upper tract urothelial carcinoma were significant risk factors for metastasis,and low metastin expression was an independent prognostic factor in bladder cancer.CONCLUSION:Metastin and metastin receptor have potential as suitable molecular biomarkers for urological cancers.However,future studies of metastin and metastin receptor should undergo external validation to ensure consistency across different patient series,since individual institutional studies lack generalization. 展开更多
关键词 KISS-1 METASTIN METASTIN RECEPTOR Metastasis Renal cell CARCINOMA Upper tract UROTHELIAL CARCINOMA BLADDER cancer
在线阅读 免费下载
高级别T1期膀胱尿路上皮癌保留膀胱术后转归分析 预览 被引量:1
16
作者 潘东亮 李宁忱 +2 位作者 晋连超 张祥华 那彦群 《中国癌症杂志》 CAS CSCD 北大核心 2012年第1期 56-59,共4页
背景与目的:对于经膀胱内治疗失败的高级别T1膀胱尿路上皮癌应积极采取膀胱全切术,但是部分患者由于某种原因接受了膀胱保留术式,其转归历程如何,到目前为止尚缺乏系统报道。本研究旨在分析高级别T1膀胱尿路上皮癌保留膀胱术后转归特... 背景与目的:对于经膀胱内治疗失败的高级别T1膀胱尿路上皮癌应积极采取膀胱全切术,但是部分患者由于某种原因接受了膀胱保留术式,其转归历程如何,到目前为止尚缺乏系统报道。本研究旨在分析高级别T1膀胱尿路上皮癌保留膀胱术后转归特点。方法:收集2005年1月—2006年2月首次在北京大学首钢医院行经尿道膀胱肿瘤切除或膀胱部分切除术的7例T1膀胱尿路上皮癌患者,术后膀胱肿瘤复发但未行膀胱全切术直至死亡全过程的临床资料。7例均采用入院诊治的方法随访。结果:7例T1膀胱癌患者均具有多发、高级别等高危因素,未行膀胱全切术原因分别是3例患者年龄过高(81、83和86岁)及4例严重心脏病。患者存活6~65个月(中位44.5个月),发生严重血尿7例、骨转移6例、肺转移5例、肝转移5例、肾上腺转移3例、胸壁转移1例,均死于膀胱癌相关事件。结论:高级别T1膀胱尿路上皮癌保留膀胱术后存活时间较短;易发生多处、远处转移,以骨、肺、肝最常见;血尿严重,无持续有效的治疗方法。 展开更多
关键词 尿路上皮 膀胱 高级别 T1期 保留膀胱
在线阅读 下载PDF
膀胱内翻性乳头状瘤与尿路上皮癌的超声特征比较
17
作者 杨帆 吴火林 +4 位作者 陈媛 黄晓娟 俞玲芳 邱建康 雷建美 《中国超声医学杂志》 CSCD 北大核心 2019年第1期52-55,共4页
目的探讨膀胱内翻性乳头状瘤(IUP)与尿路上皮癌(UC)的超声特征。方法回顾性分析经手术和病理证实的17例IUP和51例UC患者的超声表现,并比较两者的超声特征。结果 IUP的肿瘤基底部宽度要小于UC,高宽比则更大。UC更多表现为位于膀胱侧壁、... 目的探讨膀胱内翻性乳头状瘤(IUP)与尿路上皮癌(UC)的超声特征。方法回顾性分析经手术和病理证实的17例IUP和51例UC患者的超声表现,并比较两者的超声特征。结果 IUP的肿瘤基底部宽度要小于UC,高宽比则更大。UC更多表现为位于膀胱侧壁、肿瘤内可见强回声、镶边征及Ⅱ级血流信号;而钟摆征在IUP中则更为常见,上述差异均有统计学意义(P<0.05)。以肿瘤的高宽比来鉴别IUP和UC的ROC曲线下面积为0.905、最佳截断值为1.026、最佳截断值所对应的灵敏度为77.97%、特异度为97.12%。结论超声有助于IUP和UC的鉴别诊断。 展开更多
关键词 内翻性乳头状瘤 尿路上皮癌 膀胱 超声检查
上段输尿管尿路上皮细胞癌患者预后的影响因素分析 预览
18
作者 徐惠丽 韩永红 +2 位作者 王纯 卢驰 曾娟 《癌症进展》 2019年第7期856-858,共3页
目的探讨上段输尿管尿路上皮细胞癌患者预后的影响因素。方法依据预后评估结果,133例上段输尿管尿路上皮细胞癌患者中,预后不佳组56例,预后良好组77例。上段输尿管尿路上皮细胞癌患者预后的影响因素采用Logistic逐步回归分析。结果单因... 目的探讨上段输尿管尿路上皮细胞癌患者预后的影响因素。方法依据预后评估结果,133例上段输尿管尿路上皮细胞癌患者中,预后不佳组56例,预后良好组77例。上段输尿管尿路上皮细胞癌患者预后的影响因素采用Logistic逐步回归分析。结果单因素分析结果显示,不同肿块数目、肿瘤直径、病理分级、临床分期、合并慢性肾脏病情况和膀胱灌注化疗情况上段输尿管尿路上皮细胞癌患者的预后情况比较,差异均有统计学意义(P﹤0.05)。Logistic回归分析结果显示,合并慢性肾脏病、肿瘤直径≥3cm、病理分级为G3级、临床分期为Ⅱ~Ⅲ期、未接受膀胱灌注化疗均是影响上段输尿管尿路上皮细胞癌患者预后的独立危险因素。结论合并慢性肾脏病、肿瘤直径≥3cm、病理分级为G3级、临床分期为Ⅱ~Ⅲ期、未接受膀胱灌注化疗均是影响上段输尿管尿路上皮细胞癌患者预后的独立危险因素。 展开更多
关键词 上段输尿管 尿路上皮癌 预后 影响因素
在线阅读 下载PDF
PD-L1抑制剂--Atezolizumab的药理作用和临床评价 预览
19
作者 曹园园 高欢 +1 位作者 金芳 宋燕青 《实用药物与临床》 CAS 2019年第3期330-334,共5页
Atezolizumab(商品名:TecentriqTM)是由基因泰克公司开发的一种针对程序性死亡配体1(PD-L1或CD274抗原)的单克隆抗体,用于治疗各种血液恶性肿瘤和实体瘤。该药物已被FDA批准为治疗尿路上皮癌的二线药物,并有望成为非小细胞肺癌的二线治... Atezolizumab(商品名:TecentriqTM)是由基因泰克公司开发的一种针对程序性死亡配体1(PD-L1或CD274抗原)的单克隆抗体,用于治疗各种血液恶性肿瘤和实体瘤。该药物已被FDA批准为治疗尿路上皮癌的二线药物,并有望成为非小细胞肺癌的二线治疗药物。本文对其作用机制、药动学、临床研究和不良反应等进行综述。 展开更多
关键词 Atezolizumab PD-L1抑制剂 尿路上皮癌 非小细胞肺癌
在线阅读 下载PDF
术前红细胞平均血红蛋白量水平与上尿路尿路上皮癌预后的相关性分析
20
作者 谭平 杨璐 +10 位作者 徐航 艾建忠 刘振华 柳良仁 林天海 鲍一歌 金熙 曹德宏 唐钵 李响 魏强 《临床泌尿外科杂志》 2019年第2期98-103,共6页
目的:分析术前红细胞(RBC)相关指标对上尿路尿路上皮癌(UTUC)患者术后的预后影响。方法:回顾性分析2003年1月~2016年12月我院701例UTUC患者的临床资料和随访结果。结果:中位随访时间39(17~67)个月。男401例(57.2%),女300例(42.8%)。515... 目的:分析术前红细胞(RBC)相关指标对上尿路尿路上皮癌(UTUC)患者术后的预后影响。方法:回顾性分析2003年1月~2016年12月我院701例UTUC患者的临床资料和随访结果。结果:中位随访时间39(17~67)个月。男401例(57.2%),女300例(42.8%)。515例(73.5%)诊断为高级别肿瘤,pT3和pT4期分别有247例(35.2%)和100例(14.3%)。患者5年总体生存(OS)、肿瘤特异性生存(CSS)及无复发生存(RFS)分别为54.6%、60.6%及49.0%。术前患者的红细胞压积(HCT)<0.39、血红蛋白(HGB)<114g/L、平均血红蛋白量(MCH)<28.6pg、红细胞平均体积(MCV)<91.3fl、RBC<4.09×1012/L或红细胞分布宽度(RDW)>13.9%,其预后明显较差(均P<0.05)。肿瘤T分期和肿瘤分级、淋巴结转移、同时伴多种组织类型(CVH)是CSS、RFS及OS的独立预测因子;肿瘤基底类型与CSS相关(HR=1.67,95%CI:1.06~2.63,P=0.028)。MCH是CSS(HR=1.54,95%CI:1.04~2.27,P=0.032)和RFS(HR=1.46,95%CI:1.04~2.03,P=0.028)的独立预测因子。然而其他RBC相关因子仅在单因素分析时有预测价值,在多因素分析时差异均无统计学意义。结论:本研究全面分析了RBC相关因子在中国西南UTUC患者中的预后作用,研究结果表明MCH是UTUC患者术后CSS和RFS的独立预后因素。 展开更多
关键词 上尿路 尿路上皮癌 预后 危险因素
上一页 1 2 34 下一页 到第
使用帮助 返回顶部 意见反馈